Recent Company News

• 12:03 PM ET May 15, 2026
  

  StreetAccount Activist Summary: Week of 11-May

• 09:47 PM ET May 14, 2026
  

  Quick Take: Meiji FY earnings beat on pharmaceuticals strength, food segment underperformed expectations (¥3726.0000, +137)

• 09:17 PM ET May 14, 2026
  

  Meiji Seika Pharma reports positive results from phase 3 integral-1 trial of Nacubactam for treatment for CRE infection (¥3733.0000, +144)

• 02:40 AM ET May 14, 2026
  

  Meiji opposes activist LONGCHAMP SICAV's proposals (¥3589.0000, 0)

• 02:37 AM ET May 14, 2026
  

  Meiji reports FY net income attributable ¥35.08B vs FactSet ¥45.01B [7 est, ¥36.10-58.80B] (¥3589.0000, 0)

• 03:36 AM ET Apr 15, 2026
  

  Japan March estimated foreign visitor arrivals 3.6M, +3.5% y/y

• 01:43 PM ET Mar 30, 2026
  

  Meiji Seika Pharma invests in Centivax to develop next-generation universal vaccine platform (¥3878.0000, 0)

• 01:09 PM ET Mar 30, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 28-Mar

• 02:45 AM ET Mar 25, 2026
  

  Meiji lowers FY net income attributable guidance to ¥36.50B vs prior guidance ¥54.00B and FactSet ¥55.06B [6 est, ¥52.60-58.80B] (¥3950.0000, 0)

• 03:44 AM ET Mar 18, 2026
  

  Japan February estimated foreign visitor arrivals 3.5M, +6.4% y/y